ArticleJournal of comparative effectiveness research2026
First-line tumor necrosis factor inhibitor versus abatacept treatment choice in real-world patients with anticitrullinated protein antibody- and rheumatoid factor-positive rheumatoid arthritis.
Gordon Lam et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.